Dianthus Therapeutics (DNTH) Share-based Compensation (2017 - 2025)

Dianthus Therapeutics' Share-based Compensation history runs 9 years deep, the most recent figure standing at $5.8 million for Q3 2025.

• On a quarterly basis, Share-based Compensation rose 50.89% year-over-year to $5.8 million in Q3 2025; TTM through Sep 2025 was $20.7 million, a 113.7% increase from a year earlier, with the FY2024 full-year figure at $41.5 million, up 425.32% from the prior year.
• Share-based Compensation improved to $5.8 million in Q3 2025 per DNTH's latest filing, from $5.7 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $5.8 million in Q3 2025 and bottomed at $462000.0 in Q2 2023.
• The 5-year median for Share-based Compensation is $2.1 million (2021), against an average of $2.5 million.
• Across the five-year window, Share-based Compensation slumped 82.6% in 2022 and jumped 571.21% in 2024, its largest moves.
• Year by year, Share-based Compensation stood at $2.2 million in 2021, then slumped by 76.5% to $513000.0 in 2022, then soared by 41.52% to $726000.0 in 2023, then surged by 439.67% to $3.9 million in 2024, then jumped by 47.88% to $5.8 million in 2025.
• Per Business Quant, the three latest DNTH Share-based Compensation figures stand at $5.8 million (Q3 2025), $5.7 million (Q2 2025), and $5.3 million (Q1 2025).